Last reviewed · How we verify
Ascentage Pharma HQP1351 bioavailable inhibitor — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Ascentage Pharma HQP1351 bioavailable inhibitor (Ascentage Pharma HQP1351 bioavailable inhibitor) — Ascentage Pharma Group Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ascentage Pharma HQP1351 bioavailable inhibitor TARGET | Ascentage Pharma HQP1351 bioavailable inhibitor | Ascentage Pharma Group Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ascentage Pharma HQP1351 bioavailable inhibitor CI watch — RSS
- Ascentage Pharma HQP1351 bioavailable inhibitor CI watch — Atom
- Ascentage Pharma HQP1351 bioavailable inhibitor CI watch — JSON
- Ascentage Pharma HQP1351 bioavailable inhibitor alone — RSS
Cite this brief
Drug Landscape (2026). Ascentage Pharma HQP1351 bioavailable inhibitor — Competitive Intelligence Brief. https://druglandscape.com/ci/ascentage-pharma-hqp1351-bioavailable-inhibitor. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab